-
Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment
Monday, August 8, 2016 - 4:27pm | 329Read More...Deutsche Bank has cut its estimates and price target on Bristol-Myers Squibb Co (NYSE: BMY) shares following its clinical trial disappointment. Bristol-Myers said on Friday that its CheckMate-026 Study, which was investigating the use of Opdivo (nivolumab) as monotherapy, failed to meet its primary...
-
Deutsche Downgrades Ligand As Risk/Reward Becomes Challenging
Friday, August 5, 2016 - 2:25pm | 392Read More...Deutsche Bank has downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to Sell from Hold on valuation. Despite acknowledging the long-term potential of Ligand's "more than 150 shots-on-goal," the brokerage sees downside in shares over the next one year if there is lag in revenue momentum and lack...
-
A Fairly Balanced Risk And Reward Scenario For Lannett; Deutsche Bank Initiates At Hold
Wednesday, June 29, 2016 - 11:30am | 235Read More...Lannett Company, Inc. (NYSE: LCI) has a fairly balanced risk and reward scenario for the future; therefore, Deutsche Bank's Gregg Gilbert initiated Lannett at Hold and set a price target of $26. The small-cap player in the U.S. generics market had strong revenue and growth over the past few years,...
-
Is Allergan Worth Over $300 Without Pfizer?
Wednesday, April 6, 2016 - 11:57am | 310Read More...Allergan plc Ordinary Shares (NYSE: AGN) plummeted this week as news broke that Pfizer Inc. (NYSE: PFE) and Allergan will be terminating their proposed merger. The stock may have taken a hit, but a pair of Wall Street analysts believe that there’s plenty of value in a stand-alone Allergan...
-
Deutsche Bank: Valeant Stock Could Be Worth $18, $30 Or $36
Monday, April 4, 2016 - 8:35am | 289Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have plummeted 73 percent year-to-date, due to pending restatements, 10-K filing delay, and ongoing Board investigation into Philidor and accounting-related items. Deutsche Bank’s Gregg Gilbert wrote about what a theoretical model for...
-
Deutsche Bank Suspends Valeant Rating, Says It Was 'Long Skeptical' Of Business Model
Tuesday, March 1, 2016 - 11:03am | 167Read More...Deutsche Bank’s Gregg Gilbert suspending the rating and estimates for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), citing the company’s plans to restate prior results, the delay in its 10-K filing, the removal of its prior guidance for 2016, and an ongoing Board investigation....
-
Jazz Pharma Falls After Q4 Sales Miss Street View
Wednesday, February 24, 2016 - 4:39pm | 376Read More...Shares of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) fell as much as 6 percent Wednesday after the company's fourth quarter revenue fell short of Street view. The company earned $1.32 a share for the fourth quarter. Excluding items, earnings were $2.60 a share, which came in line with analysts...
-
Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought
Monday, December 7, 2015 - 10:32am | 317Read More...Eli Lilly and Co (NYSE: LLY) shares have gained 26 percent year-to-date, while still trading short of their 52-week high of $92.85. Deutsche Bank’s Gregg Gilbert upgraded the rating on the company from Hold to Buy, while raising the price target from $85 to $99. Solanezumab has the...
-
Here's Why Valeant Is Worrying Deutsche Bank And Morgan Stanley
Tuesday, November 17, 2015 - 12:19pm | 697Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are now lower by 70 percent over the past three months. Analysts at Deutsche Bank and Morgan Stanley both raised concerns on the company's business. Gregg Gilbert of Deutsche Bank noted a propriety survey with doctors indicated...
-
Endo Bought Par In One Of Biggest Generics M&A Deals Ever: What The Street's Saying
Tuesday, September 29, 2015 - 9:57am | 266Read More...Endo International plc – Ordinary Shares (NASDAQ: ENDP) are down 15 percent year-to-date, despite touching a high of $95.92 on April 15. Deutsche Bank’s Gregg Gilbert reinstated a Buy rating on the company, with a price target of $88. Improving performance of the base business...
-
How Teva Grows 'After The Cliff'
Thursday, September 24, 2015 - 11:10am | 402Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shares are down 6 percent since August 25 and have remained below the $70 mark since August 10. Deutsche Bank’s Gregg Gilbert maintained a Buy rating for the company, with a price target of $82. Although Teva’s EPS could...
-
Deutsche Bank Cuts Ligand Pharma To Hold
Monday, June 15, 2015 - 10:41am | 252Read More...In a report published Monday, Deutsche Bank analyst Gregg Gilbert downgraded the rating on Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) from Buy to Hold, with a price target of $94. The analyst believes that the risk/reward profile of the stock is more balanced at present. Both the business and the...
-
Akorn Initiated At Deutsche Bank, Notes Impressive Drug Pipeline
Wednesday, April 8, 2015 - 9:43am | 197Read More...Deutsche Bank issued a company note on Akorn, Inc. (NASDAQ: AKRX) initiating coverage on the company. Deutsche Bank rates Akorn as a Buy with a $55 price target. Analysts Gregg Gilbert and Greg Fraser wrote, "For a midcap specialty generics company, Akorn has a relatively diverse revenue base,...
-
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Tuesday, January 27, 2015 - 10:33am | 148Read More...In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert reiterated a Buy rating and $65.00 price target on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). In the report, Deutsche Bank noted, “TEVA announced a final approval for its generic version of Nexium, a $2bn product (reported US...
-
Deutsche Bank, Stifel Differ On Outlook For Eli Lilly
Thursday, January 8, 2015 - 1:46pm | 284Read More...Deutsche Bank and Stifel took differing positions on Eli Lilly and Co (NYSE: LLY) Thursday. Analyst Gregg Gilbert at Deutsche Bank downgraded the stock from Buy to Hold and maintained a $75 price target. Gilbert felt the stock had performed well in 2014, but little upside remained. “...
